This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Post #29 and I disagree about the size of the effect, not about the direction.
Small correction to my own earlier position on retatrutide discussion. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.
Worth separating retatrutide discussion as a question about the compound from retatrutide discussion as a question about the documentation. They get answered by different people and only one of them is answerable here.
No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.
That has been true for the cases I have seen and I have not seen many.
Narrowing post #33, because the general version has more than one answer.
Retatrutide is investigational. Material obtained outside a clinical trial is research-use-only by definition, is not approved for human use, and carries no assurance about its identity or content beyond whatever independent testing you commission yourself.
It is the sort of thing that seems obvious in retrospect and was not at the time.
Worth separating two things that post #33 runs together.
Adding the boring version of retatrutide discussion, because the interesting version keeps getting posted and the boring one is usually right.
Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.
This follows post #33 rather than contradicting it.
Before the thread moves on from retatrutide discussion — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.
Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.
A modest claim, modestly supported.
A theoretical mass for retatrutide is not published in the peer-reviewed literature in a form worth quoting. A report should state the mass observed on the instrument rather than assert agreement with a figure nobody can check.
Written from notes rather than memory, which is why the numbers are specific.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
The interesting part of this is the exception, and I do not understand the exception.
Building on post #38 rather than restating it.
The practical version of retatrutide discussion is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.
Post #41 put the caveat in the right place and I want to underline it.
I would keep retatrutide discussion and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.
Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in peer-reviewed literature for retatrutide at present.
That is the shape of it. The detail is where I would expect to be corrected.
Post #42 is the version of this I will quote in future. One addition.
Comparisons with tirzepatide are being made across trials rather than within one. Different populations, different durations, different endpoints; the effect sizes are not commensurable and nobody has run the head-to-head.
Triple agonism at GLP-1, GIP and glucagon receptors is the defining feature and the glucagon limb is the one people find counter-intuitive. It raises energy expenditure and promotes hepatic fat oxidation, and the incretin limbs offset the glycaemic consequence.
Correct me on the arithmetic if it is wrong; I would rather know.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
That holds under the stated conditions and I have stated them.
Retatrutide discussion is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
On analysis: a chromatographic purity figure for an investigational compound is harder to interpret than for a well-characterised one, because there is no reference standard in wide circulation and no published impurity profile to compare against.
Noting that the question and the thing people usually mean by it are different.
I had written a reply contradicting post #47 and deleted it. Here is what survived.
An observation about retatrutide discussion that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.
Confirming post #51 from a second method, which matters more than confirming it from a second person.
What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.
That is all the detail I have. Someone else will have more.
Noted, and I have changed what I was going to do on the strength of it.
Post #54 is right about the mechanism and I think understates the practical bit.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
On post #56 — agreed on the reasoning, with one qualification.
Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.
I am describing what is, rather than arguing for what should be.
Retatrutide discussion: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
Second-hand on retatrutide discussion, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.